Sanofi and Regeneron's Dupixent gets approval in EU to treat eczema in kids over 6 months
artJazz

The European Commission (EC) approved Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals' (NASDAQ:REGN) Dupixent to treat severe atopic dermatitis (eczema) in children aged six months to five years old who are eligible for systemic therapy.
The French pharma giant said that with the approval Dupixent (dupilumab) is the first and only targeted drug indicated to treat these young children in Europe and in the U.S.
In January, a panel of the European Medicines Agency (EMA) recommended granting expanded approval to Dupixent.
"With this latest approval, Dupixent is the first-ever biologic medicine for people living with atopic dermatitis from infancy to adulthood," said Naimish Patel, head of Global Development, Immunology and Inflammation at Sanofi.
The EC approval was backed by data from a phase 3 trial which showed Dupixent improved skin clearance and reduced overall disease severity and itch compared to placebo, the company noted.
Atopic dermatitis is a chronic type 2 inflammatory skin disease, characterized by itching, redness, and lesions on the skin among other things.
Dupixent is already approved in the EU to treat certain patients with prurigo nodularis, atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and eosinophilic esophagitis (EoE) in different age groups.